Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events in patients with ACS.
* **Myocardial Infarction (MI):** For patients with a history of MI, ticagrelor is indicated to reduce the rate of thrombotic cardiovascular events.
## Adult Dosing
* **ACS:** An initial loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **History of MI:** 60 mg orally twice daily.
## Pediatric Dosing
The safety and efficacy of ticagrelor in pediatric patients have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required in patients with mild to moderate renal impairment. In severe renal impairment, caution is advised, although no specific dose adjustment is recommended.
* **Hepatic Impairment:** No dose adjustment is required in patients with mild to moderate hepatic impairment. Ticagrelor is not recommended in severe hepatic impairment due to lack of data.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including major and minor), bradycardia.
* **Serious:** Significant bleeding, ventricular pauses, hyperkalemia.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor concentrations.
* **P-glycoprotein (P-gp) Inhibitors:** Strong P-gp inhibitors (e.g., cyclosporine) may increase ticagrelor exposure.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution and consider clinical monitoring.
* **Statins:** Ticagrelor can increase simvastatin and atorvastatin concentrations. Dose adjustments may be necessary.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Cardiac Rhythm:** ECG monitoring may be considered, especially in patients with risk factors for bradycardia.
* **Potassium:** Monitor serum potassium levels, particularly in patients with risk factors for hyperkalemia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, allowing for faster platelet function recovery compared to clopidogrel.
* Dyspnea is a common side effect and is usually not associated with underlying cardiac or pulmonary disease; it typically resolves with continued therapy.
* Ticagrelor should be taken twice daily, regardless of food intake.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If interruption is necessary, consider bridging therapy with an alternative agent if appropriate.
***
*Please verify the current prescribing information and institutional protocols for definitive guidance.*
